MedTrace Logo

Dexmedetomidine and Blood Coagulation

NCT04269278 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2021-07-02

No results posted yet for this study

Summary

Dexmedetomidine may alter whole blood coagulation. However, little is known about the dose-response relationships according to the blood concentration of dexmedetomidine. The investigators have therefore performed the present study to measure the effect of dexmedetomidine on the coagulation pathway according to the drug concentration level using a rotational thromboelastometry test.

Conditions

  • Blood Coagulation Disorder

Interventions

DRUG

0 ul of dexmedetomidine

Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine

DRUG

0.25 ul of dexmedetomidine

Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine

DRUG

0.5 ul of dexmedetomidine

Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine

DRUG

0.75 ul of dexmedetomidine

Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Hyo-Seok Na, MD., PhD. · Seoul National University Bundang Hospital

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-12
Primary Completion
2020-12-30
Completion
2020-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04269278 on ClinicalTrials.gov